Last updated: November 4, 2026
HYRIMOZ is Sandoz’s adalimumab biosimilar, marketed in the United States as adalimumab-adaz and in other markets as a biosimilar to AbbVie’s HUMIRA. Its commercial trajectory depends on three factors: payer acceptance, interchangeability, and price competition among multiple adalimumab biosimilars.
Sandoz launched HYRIMOZ in the United States in January 2024 after settling patent disputes with AbbVie. The product is FDA-approved as a biosimilar and interchangeable with HUMIRA in relevant presentations. Sandoz also markets an unbranded adalimumab-adaz option at a substantially lower list price than HUMIRA. Product-level revenue is not separately disclosed by Sandoz, so financial performance must be assessed through market share, pricing, and Sandoz’s broader biosimilars business.
What is HYRIMOZ and how does it compete with HUMIRA?
HYRIMOZ is a monoclonal antibody biosimilar containing adalimumab-adaz. It is used for several inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa.
| Attribute |
HYRIMOZ |
HUMIRA |
| Active ingredient |
Adalimumab-adaz |
Adalimumab |
| Sponsor |
Sandoz |
AbbVie |
| FDA pathway |
Section 351(k) biosimilar |
Original biologic |
| Initial FDA approval |
2018 |
2002 |
| Interchangeability |
FDA-designated interchangeable product |
Reference product |
| U.S. launch |
January 2024 |
2003 |
| Dosage form |
Subcutaneous injection |
Subcutaneous injection |
| Main commercial issue |
Price, payer access, substitution |
Brand loyalty and contracting |
| U.S. patent position |
Does not rely on HUMIRA patent exclusivity |
Large originator patent estate |
The FDA approved HYRIMOZ in October 2018 as a biosimilar to HUMIRA. The agency later approved a high-concentration, citrate-free presentation. FDA records identify adalimumab-adaz as interchangeable with HUMIRA for applicable presentations, allowing pharmacy-level substitution subject to state law and payer rules [1].
When did HYRIMOZ enter the U.S. market?
Sandoz entered the U.S. market in January 2024. The launch followed a settlement with AbbVie that permitted commercial entry after HUMIRA’s core U.S. exclusivity period and associated patent settlements had expired or been resolved.
The commercial launch sequence was:
| Date |
Event |
| 2018 |
FDA approves HYRIMOZ as a biosimilar to HUMIRA |
| 2021 |
FDA approves citrate-free, high-concentration presentation |
| 2023 |
FDA grants or confirms interchangeability status for applicable HYRIMOZ presentation |
| January 2024 |
Sandoz launches HYRIMOZ in the United States |
| 2024 onward |
Payers evaluate HYRIMOZ against multiple adalimumab biosimilars |
HUMIRA’s U.S. biologic exclusivity expired in 2023, based on the 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act. Patent settlements with AbbVie controlled the timing of individual biosimilar launches.
What is the pricing strategy for HYRIMOZ?
Sandoz uses a dual-price strategy:
- A branded HYRIMOZ product with a relatively modest discount to HUMIRA.
- An unbranded adalimumab-adaz product with a much deeper discount.
Sandoz announced that HYRIMOZ would be offered at a list price approximately 5% below HUMIRA’s list price, while the unbranded version would carry an approximately 81% discount to HUMIRA’s list price [2].
This structure reflects the economics of the U.S. specialty-drug market. A moderate branded discount can preserve gross-to-net economics and support payer contracting. The unbranded option targets formularies and purchasers that prioritize acquisition cost over brand recognition.
The stated discount does not equal the final net price. Actual economics depend on rebates, specialty-pharmacy fees, wholesaler discounts, patient-support programs, Medicaid rebates, and payer-specific contracts.
How large is the adalimumab biosimilar market?
The U.S. adalimumab market is one of the largest biosimilar opportunities in immunology. HUMIRA generated approximately $14.4 billion in worldwide revenue for AbbVie in 2023, down from approximately $21.2 billion in 2022 as U.S. biosimilar competition began [3].
The market is structurally different from a conventional small-molecule generic market:
- Physicians may continue prescribing HUMIRA even after biosimilar launch.
- Pharmacy substitution depends on FDA interchangeability and state law.
- Many products are distributed through specialty pharmacies.
- Payers can place biosimilars on preferred formularies without automatic substitution.
- High-concentration, citrate-free presentations have become commercially important.
- Rebates can produce a lower net price than the published list price.
The first-wave U.S. competitors include Amjevita, Cyltezo, Hadlima, Abrilada, Yusimry, and HYRIMOZ. Several sponsors use both branded and unbranded versions to address different payer segments.
Which companies compete directly with HYRIMOZ?
| Product |
Sponsor |
Reference product |
Commercial position |
| HYRIMOZ / adalimumab-adaz |
Sandoz |
HUMIRA |
Branded and unbranded strategy; interchangeable status |
| Amjevita / adalimumab-atto |
Amgen |
HUMIRA |
First major U.S. entrant; multiple pricing tiers |
| Cyltezo / adalimumab-adbm |
Boehringer Ingelheim |
HUMIRA |
Interchangeable biosimilar |
| Hadlima / adalimumab-bwwd |
Samsung Bioepis and Organon |
HUMIRA |
Branded and unbranded offerings |
| Abrilada / adalimumab-afzb |
Pfizer |
HUMIRA |
Branded biosimilar with U.S. launch |
| Yusimry / adalimumab-aqvh |
Coherus BioSciences |
HUMIRA |
Low-price commercial strategy |
The main competitive variable is not clinical differentiation. FDA biosimilarity means the products have no clinically meaningful differences from HUMIRA in safety, purity, and potency. Competition therefore centers on price, payer placement, supply reliability, device usability, and contracting.
What is the Orange Book and patent status of HYRIMOZ?
HYRIMOZ is a biologic, so it does not have an Orange Book listing in the same manner as a conventional small-molecule drug. Biologic reference-product information is maintained through the FDA’s Purple Book rather than the Orange Book [4].
AbbVie’s HUMIRA patent estate included numerous formulation, manufacturing, dosing, and device-related patents. AbbVie used patent litigation and settlement agreements to delay or sequence biosimilar entry. Sandoz was among the companies that resolved those disputes through settlement arrangements.
Because HYRIMOZ is a biosimilar, its U.S. commercial access depended primarily on:
- FDA approval under the 351(k) pathway.
- Resolution of AbbVie patent claims.
- Settlement-defined entry timing.
- Freedom to market approved presentations.
- Compliance with manufacturing and labeling requirements.
Publicly available sources do not identify a separate, broad HYRIMOZ composition-of-matter patent estate comparable to HUMIRA’s originator estate. The commercial protection is regulatory and contractual rather than based on a new molecular patent.
What formulation patents protect HYRIMOZ or HUMIRA?
HUMIRA’s later commercial value was supported by high-concentration, citrate-free formulations, prefilled pens, syringes, and injection-device configurations. These changes improved administration characteristics and reduced injection volume or discomfort compared with earlier formulations.
HYRIMOZ competes through corresponding presentations, including citrate-free, high-concentration options. Formulation and device claims can still affect market access even when the underlying biologic is no longer protected by core exclusivity.
Relevant formulation barriers include:
- Concentration and buffer composition.
- Citrate-free formulation.
- Injection volume.
- Prefilled syringe and autoinjector configuration.
- Container closure and stability.
- Cold-chain handling.
- Manufacturing consistency for a complex monoclonal antibody.
These factors do not necessarily prevent approval of a biosimilar. They can affect which presentation is commercially available and whether a sponsor can launch a particular device or formulation without additional patent litigation.
Does HYRIMOZ have biosimilar or generic entry risk?
HYRIMOZ itself is not exposed to conventional generic substitution in the same way as a small-molecule product. The more important risk is biosimilar price erosion from rival adalimumab products.
The principal risks are:
| Risk |
Effect on HYRIMOZ |
| Multiple interchangeable biosimilars |
Reduces negotiating leverage |
| Aggressive unbranded pricing |
Compresses net price |
| Payer exclusion |
Limits prescription volume |
| HUMIRA rebate response |
Can slow biosimilar conversion |
| Physician conservatism |
Delays switching of stable patients |
| Specialty-pharmacy control |
Increases access friction |
| Manufacturing interruption |
Creates substitution opportunities for rivals |
Interchangeability improves HYRIMOZ’s position, but it does not guarantee automatic substitution nationwide. State pharmacy laws and payer policies determine whether a pharmacist can replace HUMIRA without prescriber intervention.
What is the financial trajectory for HYRIMOZ?
Sandoz does not publicly report HYRIMOZ revenue as a separate product line. Its financial trajectory must therefore be inferred from the broader biosimilars portfolio and market conditions.
The likely trajectory has four phases:
Launch phase
The launch period is characterized by high contracting costs, limited formulary history, and uncertain switching behavior. Revenue is likely to build gradually as payers establish preferred products and specialty pharmacies update protocols.
Share-capture phase
HYRIMOZ can gain share through its interchangeable status, Sandoz’s biosimilars commercial infrastructure, and the availability of a deeply discounted unbranded option. Growth depends on whether payers prefer Sandoz over Amgen, Boehringer Ingelheim, Organon, Pfizer, or Coherus.
Price-pressure phase
As more biosimilars compete, the market is likely to experience lower net prices. Volume may increase while revenue per unit declines. A branded product can preserve some margin, but unbranded contracting can accelerate price compression.
Mature-market phase
The mature market will likely resemble a multi-supplier specialty market rather than a single generic collapse. Stable patients may remain on HUMIRA, while new starts and payer-mandated switches move toward biosimilars. Product economics will depend more on procurement scale and manufacturing reliability than on clinical differentiation.
For Sandoz, HYRIMOZ is strategically important because adalimumab expands its immunology portfolio and supports its standalone biosimilars platform. It is unlikely to match the absolute revenue scale HUMIRA generated for AbbVie because the market is divided among several suppliers and discounts are substantial.
What is the litigation and settlement outlook for HYRIMOZ?
The major litigation risk was AbbVie’s patent enforcement against adalimumab biosimilar developers. Sandoz’s settlement resolved the principal launch-timing dispute for the United States.
After launch, litigation risk is more likely to involve:
- Presentation-specific formulation patents.
- Injection devices.
- Manufacturing processes.
- Labeling and induced-infringement claims.
- Contract disputes with payers or pharmacy-benefit managers.
- Patent challenges involving later-developed delivery systems.
No broad, publicly reported post-launch litigation wave has displaced HYRIMOZ from the U.S. market through the initial launch period.
How does HYRIMOZ compare with Cyltezo and Amjevita?
HYRIMOZ has two important advantages: an interchangeable designation and Sandoz’s established biosimilar commercial platform. Cyltezo also has interchangeable status and competes directly on substitution potential.
Amjevita entered the U.S. market earlier and benefited from first-mover experience, but it faces the same pricing and formulary pressures as the rest of the market. HYRIMOZ’s unbranded pricing gives Sandoz a tool for highly cost-sensitive accounts.
| Factor |
HYRIMOZ |
Cyltezo |
Amjevita |
| Sponsor strength |
Sandoz biosimilars platform |
Boehringer Ingelheim |
Amgen |
| Interchangeability |
Yes, for applicable presentation |
Yes |
Product-specific regulatory status |
| Pricing flexibility |
Branded plus unbranded |
Branded and contracting options |
Multiple pricing strategies |
| Launch timing |
2024 U.S. launch |
2023 U.S. launch |
January 2023 |
| Main advantage |
Price architecture and biosimilar expertise |
Interchangeability and commercial reach |
First-mover scale |
Key Takeaways
- HYRIMOZ is Sandoz’s adalimumab-adaz biosimilar to HUMIRA.
- Sandoz launched HYRIMOZ in the United States in January 2024.
- The product is available in branded and unbranded forms, with the unbranded version positioned at a substantially deeper discount.
- HYRIMOZ competes against at least five other major U.S. adalimumab biosimilars.
- Product-level revenue is not separately disclosed by Sandoz.
- The principal commercial risks are payer exclusion, rebate competition, and rapid net-price erosion.
- HYRIMOZ has regulatory and interchangeability advantages, but those advantages do not guarantee automatic pharmacy substitution.
- HUMIRA’s patent and regulatory exclusivity no longer prevents U.S. biosimilar competition.
- The long-term market is likely to be volume-driven, with lower prices and fragmented share among multiple suppliers.
FAQs
Is HYRIMOZ interchangeable with HUMIRA?
Yes. FDA records identify applicable HYRIMOZ presentations as interchangeable with HUMIRA. Actual substitution depends on state pharmacy law and payer policy.
Is HYRIMOZ cheaper than HUMIRA?
Sandoz announced a branded HYRIMOZ list price approximately 5% below HUMIRA and an unbranded adalimumab-adaz version approximately 81% below HUMIRA’s list price. Net prices vary by contract.
Does HYRIMOZ have an Orange Book patent listing?
No. Biologics are generally tracked through the FDA Purple Book rather than the Orange Book. HUMIRA’s patent disputes were handled through biologic patent litigation and settlement agreements.
Who manufactures HYRIMOZ?
HYRIMOZ is commercialized by Sandoz, a global biosimilars and generic-drug company. Manufacturing may involve multiple approved facilities and supply-chain partners identified in regulatory filings and product labeling.
Can HYRIMOZ replace HUMIRA automatically at the pharmacy?
Not universally. FDA interchangeability supports pharmacy substitution, but the legal ability to substitute depends on the law of the state where the prescription is filled and the applicable payer rules.
References
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Sandoz. (2024). Sandoz launches Hyrimoz and unbranded adalimumab-adaz in the United States.
- AbbVie Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar biological products.